Prestige Brands Holdings Inc (PBH)

$69.8

+0.13

(+0.19%)▲

Market is closed - opens 7 PM, 23 Apr 2024

Performance

  • $69.50
    $70.82
    $69.80
    downward going graph

    0.43%

    Downside

    Day's Volatility :1.86%

    Upside

    1.44%

    downward going graph
  • $55.96
    $75.31
    $69.80
    downward going graph

    19.83%

    Downside

    52 Weeks Volatility :25.69%

    Upside

    7.32%

    downward going graph

Returns

PeriodPrestige Brands Holdings Inc
3 Months
13.17%
6 Months
17.98%
1 Year
11.65%
3 Years
55.48%

Highlights

Market Capitalization
3.5B
Book Value
$32.24
Earnings Per Share (EPS)
-1.61
PEG Ratio
1.86
Wall Street Target Price
75.6
Profit Margin
-7.11%
Operating Margin TTM
30.71%
Return On Assets TTM
6.16%
Return On Equity TTM
-4.91%
Revenue TTM
1.1B
Revenue Per Share TTM
22.8
Quarterly Revenue Growth YOY
2.6%
Gross Profit TTM
627.9M
EBITDA
380.2M
Diluted Eps TTM
-1.61
Quarterly Earnings Growth YOY
0.02
EPS Estimate Current Year
4.33
EPS Estimate Next Year
4.63
EPS Estimate Current Quarter
1.04
EPS Estimate Next Quarter
1.14

Analyst Recommendation

Buy
    80%Buy
    20%Hold
    0
    0%Sell
Based on 10 Wall street analysts offering stock ratings for Prestige Brands Holdings Inc(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
8
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 8.31%

Current $69.80
Target $75.60

Company Financials

FY18Y/Y Change
Revenue
1.0B
↑ 18.04%
Net Income
339.6M
↑ 389.33%
Net Profit Margin
32.61%
↑ 24.74%
FY19Y/Y Change
Revenue
975.8M
↓ 6.28%
Net Income
-35.8M
↓ 110.54%
Net Profit Margin
-3.67%
↓ 36.28%
FY20Y/Y Change
Revenue
963.0M
↓ 1.31%
Net Income
142.3M
↓ 497.43%
Net Profit Margin
14.77%
↑ 18.44%
FY21Y/Y Change
Revenue
943.4M
↓ 2.04%
Net Income
164.7M
↑ 15.74%
Net Profit Margin
17.46%
↑ 2.69%
FY22Y/Y Change
Revenue
1.1B
↑ 15.21%
Net Income
205.4M
↑ 24.71%
Net Profit Margin
18.9%
↑ 1.44%
FY23Y/Y Change
Revenue
1.1B
↑ 3.76%
Net Income
-82.3M
↓ 140.07%
Net Profit Margin
-7.3%
↓ 26.2%
Q3 FY22Q/Q Change
Revenue
289.3M
↑ 4.41%
Net Income
51.0M
↓ 7.69%
Net Profit Margin
17.64%
↓ 2.31%
Q4 FY22Q/Q Change
Revenue
275.5M
↓ 4.75%
Net Income
52.0M
↑ 1.82%
Net Profit Margin
18.86%
↑ 1.22%
Q1 FY23Q/Q Change
Revenue
285.9M
↑ 3.75%
Net Income
-240.6M
↓ 563.04%
Net Profit Margin
-84.15%
↓ 103.01%
Q2 FY23Q/Q Change
Revenue
279.3M
↓ 2.29%
Net Income
53.3M
↓ 122.15%
Net Profit Margin
19.07%
↑ 103.22%
Q3 FY23Q/Q Change
Revenue
286.3M
↑ 2.51%
Net Income
53.6M
↑ 0.53%
Net Profit Margin
18.71%
↓ 0.36%
Q4 FY23Q/Q Change
Revenue
282.7M
↓ 1.25%
Net Income
53.0M
↓ 0.96%
Net Profit Margin
18.76%
↑ 0.05%
FY18Y/Y Change
Total Assets
3.8B
↓ 3.85%
Total Liabilities
2.6B
↓ 16.41%
FY19Y/Y Change
Total Assets
3.4B
↓ 8.5%
Total Liabilities
2.3B
↓ 9.17%
FY20Y/Y Change
Total Assets
3.5B
↑ 2.12%
Total Liabilities
2.3B
↓ 0.1%
FY21Y/Y Change
Total Assets
3.4B
↓ 2.41%
Total Liabilities
2.1B
↓ 11.61%
FY22Y/Y Change
Total Assets
3.7B
↑ 7.04%
Total Liabilities
2.1B
↑ 1.07%
FY23Y/Y Change
Total Assets
3.4B
↓ 8.63%
Total Liabilities
1.9B
↓ 8.91%
Q3 FY22Q/Q Change
Total Assets
3.7B
↓ 0.1%
Total Liabilities
2.1B
↓ 1.85%
Q4 FY22Q/Q Change
Total Assets
3.7B
↑ 1.94%
Total Liabilities
2.1B
↑ 0.21%
Q1 FY23Q/Q Change
Total Assets
3.4B
↓ 10.56%
Total Liabilities
1.9B
↓ 7.58%
Q2 FY23Q/Q Change
Total Assets
3.3B
↓ 0.24%
Total Liabilities
1.9B
↓ 2.17%
Q3 FY23Q/Q Change
Total Assets
3.3B
↓ 0.38%
Total Liabilities
1.8B
↓ 3.67%
Q4 FY23Q/Q Change
Total Assets
3.3B
↑ 0.21%
Total Liabilities
1.7B
↓ 3.21%
FY18Y/Y Change
Operating Cash Flow
210.1M
↑ 42.19%
Investing Cash Flow
-11.6M
↓ 98.34%
Financing Cash Flow
-209.0M
↓ 137.19%
FY19Y/Y Change
Operating Cash Flow
189.3M
↓ 9.91%
Investing Cash Flow
55.4M
↓ 579.43%
Financing Cash Flow
-249.3M
↑ 19.32%
FY20Y/Y Change
Operating Cash Flow
217.1M
↑ 14.71%
Investing Cash Flow
-16.6M
↓ 129.89%
Financing Cash Flow
-131.4M
↓ 47.29%
FY21Y/Y Change
Operating Cash Flow
235.6M
↑ 8.51%
Investing Cash Flow
-22.2M
↑ 34.24%
Financing Cash Flow
-279.4M
↑ 112.6%
FY22Y/Y Change
Operating Cash Flow
259.9M
↑ 10.32%
Investing Cash Flow
-256.5M
↑ 1053.22%
Financing Cash Flow
-7.6M
↓ 97.29%
FY23Y/Y Change
Operating Cash Flow
229.7M
↓ 11.62%
Investing Cash Flow
-11.6M
↓ 95.48%
Financing Cash Flow
-185.8M
↑ 2355.36%
Q3 FY22Q/Q Change
Operating Cash Flow
57.5M
↓ 1.21%
Investing Cash Flow
-2.4M
↑ 126.93%
Financing Cash Flow
-48.0M
↑ 1.23%
Q4 FY22Q/Q Change
Operating Cash Flow
54.9M
↓ 4.52%
Investing Cash Flow
-1.8M
↓ 24.12%
Financing Cash Flow
-10.0M
↓ 79.1%
Q1 FY23Q/Q Change
Operating Cash Flow
59.0M
↑ 7.36%
Investing Cash Flow
-6.4M
↑ 252.63%
Financing Cash Flow
-80.5M
↑ 703.26%
Q2 FY23Q/Q Change
Operating Cash Flow
48.1M
↓ 18.48%
Investing Cash Flow
2.3M
↓ 136.54%
Financing Cash Flow
-54.2M
↓ 32.69%
Q3 FY23Q/Q Change
Operating Cash Flow
62.5M
↑ 29.89%
Investing Cash Flow
-611.0K
↓ 126.3%
Financing Cash Flow
-53.5M
↓ 1.16%

Technicals Summary

Sell

Neutral

Buy

Prestige Brands Holdings Inc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Prestige Brands Holdings Inc
Prestige Brands Holdings Inc
-2.68%
17.98%
11.65%
55.48%
143.94%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
-6.67%
22.32%
27.46%
36.77%
64.84%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
-0.83%
-0.6%
-6.49%
10.93%
12.82%
Zoetis Inc.
Zoetis Inc.
-13.26%
-12.01%
-16.93%
-13.35%
46.32%
Viatris Inc.
Viatris Inc.
-4.98%
26.12%
20.58%
-15.79%
-31.15%
Catalent, Inc.
Catalent, Inc.
-0.62%
31.41%
24.72%
-50.99%
26.1%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Prestige Brands Holdings Inc
Prestige Brands Holdings Inc
18.89
NA
1.86
4.33
-0.05
0.06
NA
32.24
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
53.44
53.44
0.44
4.78
0.13
0.09
NA
22.61
Haleon Plc Spon Ads
Haleon Plc Spon Ads
29.04
29.04
1.69
0.45
0.07
0.04
0.03
1.8
Zoetis Inc.
Zoetis Inc.
28.82
28.82
2.58
5.8
0.5
0.13
0.01
10.9
Viatris Inc.
Viatris Inc.
222.4
222.4
NA
2.78
0.0
0.03
0.04
17.05
Catalent, Inc.
Catalent, Inc.
211.02
NA
2.06
0.48
-0.3
-0.01
NA
20.41
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Prestige Brands Holdings Inc
Prestige Brands Holdings Inc
Buy
$3.5B
143.94%
18.89
-7.11%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$13.3B
64.84%
53.44
13.23%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
Buy
$37.1B
12.82%
29.04
9.28%
Zoetis Inc.
Zoetis Inc.
Buy
$66.8B
46.32%
28.82
27.43%
Viatris Inc.
Viatris Inc.
Hold
$13.2B
-31.15%
222.4
0.35%
Catalent, Inc.
Catalent, Inc.
Hold
$10.1B
26.1%
211.02
-31.77%

Institutional Holdings

  • BlackRock Inc

    18.27%

  • Vanguard Group Inc

    11.59%

  • Dimensional Fund Advisors, Inc.

    6.92%

  • Macquarie Group Ltd

    6.17%

  • Ariel Investments, LLC

    5.15%

  • State Street Corporation

    4.03%

Company Information

at prestige brands, now prestige consumer healthcare, we focus on product innovation and quality in over-the-counter healthcare products to improve the lives of our customers worldwide. you may not know who prestige consumer healthcare is, but you know and use our products: clear eyes, dentek, summer's eve, monistat, bc, goody's, dramamine, and many more. for generations, our trusted brands have helped consumers care for themselves and their loved ones. our mission is to preserve this trust by continuing to provide products stewarded with our customer needs in mind. prestige consumer healthcare is a different kind of company. we are the largest independent provider of over-the-counter healthcare products in north america yet we are nimble enough to give detailed attention to each and every one of our product offerings. we are constantly improving, creating products that match the ever-changing lifestyles and needs of people and families everywhere. prestige’s success as a company is th

Organization
Prestige Brands Holdings Inc
Employees
560
CEO
Mr. Ronald M. Lombardi
Industry
Health Technology

Discover More

FAQs